|
KMID : 0614720160590030180
|
|
Journal of Korean Medical Association
2016 Volume.59 No. 3 p.180 ~ p.188
|
|
|
Targeted therapy and immunotherapy in ovarian cancer
|
|
김재원:Kim Jae-Won
저자없음:No authors listed
|
|
|
Abstract
|
|
|
|
Epithelial ovarian cancer is one of the last treatment areas to be influenced by the 'personalized medicine' bandwagon. Some anti-angiogenic agents, poly (ADP-ribose) polymerase (PARP), and immune checkpoint inhibitors have shown efficacy in early stages of development for the treatment of epithelial ovarian cancer. As a result of vigorous clinical trials, bevacizumab, cediranib, pazopanib, olaparib, and rucaparib, either used alone or in adjunct to conventional cytotoxic agents, have all been shown to improve progression-free survival in first-line/maintenance, platinum-resistant or sensitive recurrent settings. A biomarker for bevacizumab is currently elusive. Olaparib is the first drug approved for the treatment of high-grade serous tumors and requires routine testing for BRCA mutation. Trial results of PARP inhibitors in the homologous recombination-deficient (non BRCA mutation) population are awaited and the introduction of these agents into the clinic will require robust methods of detecting homologous recombination-deficiency. Second-generation studies combining anti-angiogenic agents with PARP inhibitors are in progress and early results in the recurrent setting are encouraging. Trials with immune checkpoint inhibitors such as nivolumab produced prolonged responses in a small set of ovarian cancer cases and need further exploration, for example in combination with anti-angiogenic agents. The application of targeted agents and immunologics, alone or in combination, to induce a survival advantage in patients with epithelial ovarian cancer should be continued.
|
|
|
KEYWORD
|
|
|
Targeted therapy, Immunotherapy, Ovarian neoplasms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|